Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Grit Bio Closes $60 Million Round for Tumor-Infiltrating Lymphocyte Oncology Drugs

publication date: Sep 8, 2023

Shanghai Grit Biotechnology, a cell therapy company, raised more than $60 million in a Series B financing round to develop its pipeline of drugs based on Tumor-Infiltrating lymphocytes. The company’s lead drug, GT101, has started a pivotal Phase II trial for solid tumor cancers. TIL uses lymphoctyes (T cells and B cells) derived from a tumor biopsy, expands them, and infuses the cells back into the patient. Unlike CAR-T therapies, TIL candidates naturally target the tumor, and they typically attack multiple targets in the tumor. The B Round was led by CICC. More details....

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital